Aurinia Pharmaceuticals
AUPH
167 hedge funds and large institutions have $641M invested in Aurinia Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 62 increasing their positions, 40 reducing their positions, and 33 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 40
9% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 33
2% less funds holding
Funds holding: 170 → 167 (-3)
2.69% less ownership
Funds ownership: 41.24% → 38.55% (-2.7%)
6% less capital invested
Capital invested by funds: $683M → $641M (-$41.7M)
20% less call options, than puts
Call options by funds: $34M | Put options by funds: $42.5M
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$42.2M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$13.5M |
| 3 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
+$6.67M |
| 4 |
Jane Street
New York
|
+$3.18M |
| 5 |
SGA
Sector Gamma AS
Oslo,
Norway
|
+$2.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$23.2M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$20.9M |
| 3 |
HM
HealthCor Management
New York
|
-$12.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$10M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$9.27M |
AUPH Hedge Fund Activity: Q2 2021 in Review
167 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q2 2021, worth a combined $641M — down 6.1% from $683M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of AUPH and 30 opened new positions — a net loss of 3 holders — while 40 trimmed existing stakes and 62 added.
The largest buyer was Morgan Stanley, adding an estimated $42.2M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $23.2M sold.
- 167 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q2 2021, down from 170 in Q1 2021.
- Funds reported $641M of Aurinia Pharmaceuticals stock for Q2 2021, down 6.1% quarter-over-quarter.
- 30 funds opened new Aurinia Pharmaceuticals positions in Q2 2021 and 33 closed out, a net change of -3 holders.
- The largest Aurinia Pharmaceuticals buyer in Q2 2021 was Morgan Stanley, an estimated $42.2M added.
- The largest Aurinia Pharmaceuticals seller in Q2 2021 was Avidity Partners Management, an estimated $23.2M sold.
Based on aggregated 13F filings for Q2 2021.